MX2024001597A - Composicion y metodo para el tratamiento de la neuropatia optica hereditaria de leber causada por una mutacion en nd4. - Google Patents
Composicion y metodo para el tratamiento de la neuropatia optica hereditaria de leber causada por una mutacion en nd4.Info
- Publication number
- MX2024001597A MX2024001597A MX2024001597A MX2024001597A MX2024001597A MX 2024001597 A MX2024001597 A MX 2024001597A MX 2024001597 A MX2024001597 A MX 2024001597A MX 2024001597 A MX2024001597 A MX 2024001597A MX 2024001597 A MX2024001597 A MX 2024001597A
- Authority
- MX
- Mexico
- Prior art keywords
- leber
- mutation
- treatment
- composition
- nucleic acid
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title 1
- 201000001119 neuropathy Diseases 0.000 title 1
- 230000007823 neuropathy Effects 0.000 title 1
- 230000003287 optical effect Effects 0.000 title 1
- 208000033808 peripheral neuropathy Diseases 0.000 title 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 abstract 3
- 108010058682 Mitochondrial Proteins Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 108091026890 Coding region Proteins 0.000 abstract 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 abstract 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110899561 | 2021-08-06 | ||
| PCT/CN2022/110545 WO2023011632A1 (zh) | 2021-08-06 | 2022-08-05 | 用于治疗由于nd4突变造成的莱伯氏遗传性视神经病变的组合物和方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001597A true MX2024001597A (es) | 2024-02-15 |
Family
ID=85155306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001597A MX2024001597A (es) | 2021-08-06 | 2022-08-05 | Composicion y metodo para el tratamiento de la neuropatia optica hereditaria de leber causada por una mutacion en nd4. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240376164A1 (https=) |
| EP (1) | EP4382601A4 (https=) |
| JP (1) | JP2024529033A (https=) |
| KR (1) | KR20240042489A (https=) |
| CN (1) | CN116024266A (https=) |
| AR (1) | AR126727A1 (https=) |
| AU (1) | AU2022322957A1 (https=) |
| BR (1) | BR112024002305A2 (https=) |
| CA (1) | CA3228344A1 (https=) |
| MX (1) | MX2024001597A (https=) |
| WO (1) | WO2023011632A1 (https=) |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US6024983A (en) | 1986-10-24 | 2000-02-15 | Southern Research Institute | Composition for delivering bioactive agents for immune response and its preparation |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| DK0678034T3 (da) | 1993-01-11 | 1999-11-08 | Dana Farber Cancer Inst Inc | Induktion af cytotoksiske T-lymfocytreaktioner |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| CN1206361C (zh) * | 1999-09-10 | 2005-06-15 | 本元正阳基因技术股份有限公司 | 系列通用型腺病毒伴随病毒载体的构建及用途 |
| CN102634527B (zh) * | 2012-04-11 | 2013-11-06 | 华中科技大学同济医学院附属同济医院 | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 |
| CN111068071A (zh) * | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传学视神经病变 |
| CN113528510A (zh) * | 2018-06-29 | 2021-10-22 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| SG11202101032VA (en) * | 2018-08-20 | 2021-02-25 | Wuhan Neurophth Biotechnology Ltd Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| EP3908656A4 (en) * | 2019-01-07 | 2022-10-05 | California Institute of Technology | GAS VESICLE EXPRESSION SYSTEMS, GAS VESICLE CONSTRUCTS AND ASSOCIATED GENETIC CIRCUITS, VECTORS, MAMMALIAN CELLS, HOSTS, COMPOSITIONS, METHODS AND SYSTEMS |
| CN113025633B (zh) * | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| WO2021138559A1 (en) * | 2019-12-31 | 2021-07-08 | Swanbio Therapeutics Limited | Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn) |
-
2022
- 2022-08-05 AR ARP220102119A patent/AR126727A1/es unknown
- 2022-08-05 CA CA3228344A patent/CA3228344A1/en active Pending
- 2022-08-05 CN CN202210938308.5A patent/CN116024266A/zh active Pending
- 2022-08-05 JP JP2024506984A patent/JP2024529033A/ja active Pending
- 2022-08-05 MX MX2024001597A patent/MX2024001597A/es unknown
- 2022-08-05 AU AU2022322957A patent/AU2022322957A1/en active Pending
- 2022-08-05 WO PCT/CN2022/110545 patent/WO2023011632A1/zh not_active Ceased
- 2022-08-05 EP EP22852343.7A patent/EP4382601A4/en active Pending
- 2022-08-05 KR KR1020247007322A patent/KR20240042489A/ko active Pending
- 2022-08-05 US US18/294,582 patent/US20240376164A1/en active Pending
- 2022-08-05 BR BR112024002305A patent/BR112024002305A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR126727A1 (es) | 2023-11-08 |
| CA3228344A1 (en) | 2023-02-09 |
| AU2022322957A1 (en) | 2024-03-21 |
| KR20240042489A (ko) | 2024-04-02 |
| BR112024002305A2 (pt) | 2024-04-30 |
| WO2023011632A1 (zh) | 2023-02-09 |
| CN116024266A (zh) | 2023-04-28 |
| US20240376164A1 (en) | 2024-11-14 |
| EP4382601A4 (en) | 2025-07-30 |
| JP2024529033A (ja) | 2024-08-01 |
| EP4382601A1 (en) | 2024-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010321A2 (pt) | Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase | |
| MX2020013772A (es) | Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber. | |
| UY39060A (es) | Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2 | |
| BR112022019782A2 (pt) | Construtos de rna e usos dos mesmos | |
| PA8549701A1 (es) | Vacunacion en dosis unica con mycoplasma hyopneumoniae | |
| AR086272A2 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| CO2023009633A2 (es) | Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal | |
| ECSP23034907A (es) | Ácido nucleico que codifica una entidad antivegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneración macular relacionada con la edad | |
| DE69840998D1 (de) | Ricin-ähnliche toxine zur therapie von kreb, viraler oder parasitärer infektionen | |
| MX2024001597A (es) | Composicion y metodo para el tratamiento de la neuropatia optica hereditaria de leber causada por una mutacion en nd4. | |
| ECSP23093588A (es) | Composiciones de suministro de terapia génica y métodos para tratar perdida auditiva | |
| CO2024002315A2 (es) | Sistemas de edición de gen que comprenden una guía de arn dirigida a estatmina 2 (stmn2) y usos de los mismos | |
| AR125199A1 (es) | Edición génica cish de linfocitos infiltrantes de tumores y usos de los mismos en inmunoterapia | |
| BR112023000200A2 (pt) | Construção de ácido nucleico, plasmídeo de cromossomo artificial bacteriano (bac), rna vírus, processo para recuperar rna vírus, preparação de semente, vacinas e ribonucleoproteína | |
| BR112022026248A2 (pt) | Conjugados de citocinas | |
| MX2024003910A (es) | Composiciones de administración de terapia génica y métodos para tratar la pérdida auditiva. | |
| AR122379A1 (es) | Composiciones inmunogénicas y vacunas de covid-19 vectorizadas con sarampión | |
| CL2024003295A1 (es) | Ácido nucleico aislado que codifica proteína de fusión basada en fviii-bdd y péptido señal heterólogo | |
| MX2024012693A (es) | Composiciones y metodos para la prevencion y el tratamiento de la infeccion por el virus de la rabia | |
| AR133109A1 (es) | Composiciones para modular el empalme | |
| AR045000A1 (es) | Gen y proteina de eimeria , y su uso | |
| DOP2023000132A (es) | Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1 | |
| MX2023011502A (es) | Proteina de fusion inmunogenica. | |
| CL2024003296A1 (es) | Ácido nucleico codón optimizado que codifica proteína del factor viii coagulación de dominio b suprimido |